{"product_id":"dtil-five-forces","title":"(DTIL) Precision BioSciences, Inc. Porters Five Forces Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eA Must-Have Tool for Decision-Makers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Precision BioSciences, Inc. Porter's Five Forces Analysis helps you assess the competitive pressures shaping the company’s market position and profitability. The page already shows a real preview of the analysis, so you can review the actual content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSuppliers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized GMP inputs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrecision BioSciences depends on highly specialized GMP reagents, vectors, and cell-processing consumables, so supplier power is moderate to high. A small pool of vendors can meet clinical-grade standards for gene-editing and cell-therapy work, which gives them pricing and delivery leverage. Any shortage, failed lot, or quality deviation can delay programs and lift operating costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSingle-source process dependencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrecision BioSciences, Inc.’s ARCUS and CAR T work can depend on narrow inputs and validated CDMO slots, so supplier leverage is high in clinical development. Once a process is locked, changing a raw-material vendor or manufacturing partner can trigger revalidation and comparability work, which is slow and costly. That makes critical reagents and CDMO capacity the biggest pressure points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract manufacturing leverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrecision BioSciences, Inc. depends on outside labs and manufacturers for parts of development and supply, so contract organizations can hold real leverage. In cell and gene therapy, GMP capacity stays tight and booking slots can stretch timelines, shift batch access, and raise costs. Because Precision BioSciences is still small and clinical-stage, it has less room to push for long-term pricing or priority terms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eProprietary platform reduces some dependence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eARCUS is Precision BioSciences, Inc.’s internal editing engine, so it does not rely on outside licensors for its core IP. That cuts supplier power in the technology sense, because the key asset is owned in-house. Still, Precision BioSciences, Inc. must buy external analytics, CRO support, and manufacturing capacity to advance programs.\u003c\/p\u003e\n\u003cp\u003eSo supplier power is moderate, not low: the core platform is protected, but trial execution still depends on third-party tools and infrastructure. One clean read: the science is internal, the operating stack is not.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInternal ARCUS lowers IP supplier leverage\u003c\/li\u003e\n\u003cli\u003eExternal CROs and CDMOs still matter\u003c\/li\u003e\n\u003cli\u003eSupplier power stays moderate\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTalent as a supplier class\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn Precision BioSciences, Inc., skilled gene-editing, clinical, regulatory, and manufacturing talent is a supplier class because it delivers critical know-how. In biotech, scarce experts can lift pay and slow programs, so supplier power is indirect but real.\u003c\/p\u003e\n\u003cp\u003eThat matters more when hiring is tight and timelines are short. If Precision BioSciences, Inc. loses one key CMC, regulatory, or editing hire, execution risk rises fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialized talent is scarce\u003c\/li\u003e\n\u003cli\u003ePay pressure can rise fast\u003c\/li\u003e\n\u003cli\u003eExecution can slow on gaps\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision BioSciences Faces High Supplier Dependence in Key Trial Inputs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrecision BioSciences, Inc. faces moderate-to-high supplier power because GMP reagents, CDMO slots, and specialized talent are scarce. ARCUS is owned in-house, but trial work still depends on outside manufacturing and validation, so any shortage or lot failure can slow programs and raise costs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSupplier driver\u003c\/th\u003e\n\u003cth\u003ePower\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGMP reagents\/CDMOs\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eARCUS IP\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialized talent\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eTailored analysis of Precision BioSciences, Inc.'s competitive forces, supplier power, buyer influence, threats, and entry barriers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuickly spot Precision BioSciences’ competitive pressures in one clean view—saving time on strategic analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003ePrecision BioSciences, Inc. Reference Sources provide a credible audit trail that boosts trust and helps decision-makers verify key claims fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFew direct commercial buyers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrecision BioSciences, Inc. is still clinical-stage, so it has no broad commercial customer base and little direct product revenue. Demand is concentrated in a few collaborators, licensors, and trial partners today, with healthcare payers only relevant if products reach market. That makes bargaining power high, because one large partner can push hard on economics and control terms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBig pharma partner leverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrecision BioSciences depends on a small set of big pharma partners, so customer bargaining power is high. Partners like Servier usually bring far more capital and options, and they can press on milestone timing, program priority, and revenue split terms. That balance means Precision gains funding and reach, but the partner often keeps the stronger hand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFuture payer sensitivity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIf Precision BioSciences commercializes its therapies, payers and hospital systems will shape access. Gene therapies already face extreme price scrutiny: CASGEVY is priced at about $2.2 million per patient and LYFGENIA at $3.0 million. Reimbursement can slow uptake unless outcomes are strong and durable, so future buyers will have real leverage over market access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinician and trial-site influence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFor Precision BioSciences, Inc., clinician and trial-site power is moderate to high because they decide whether a development-stage therapy gets used in studies and later prescribed. In oncology, only about 3% to 7% of drugs that enter Phase 1 reach approval, so these buyers favor strong safety, durable responses, and simple dosing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSite choice can shift trial enrollment fast.\u003c\/li\u003e\n\u003cli\u003eSafer, easier therapies win adoption.\u003c\/li\u003e\n\u003cli\u003eBetter logistics can beat small efficacy gaps.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePatients have limited switching power today\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePatients in relapsed or refractory cancers have limited switching power because treatment choices are often scarce, so Precision BioSciences, Inc. faces less direct price pressure from them. Still, tolerability, access, and dosing convenience matter a lot, and those preferences can shape trial enrollment and post-approval uptake. In practice, patient power is low, but it can still move adoption.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFew options reduce bargaining leverage\u003c\/li\u003e\n\u003cli\u003eSide effects can change demand fast\u003c\/li\u003e\n\u003cli\u003eConvenience affects trial recruitment\u003c\/li\u003e\n\u003cli\u003eAcceptance still depends on patient choice\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision BioSciences Faces Strong Buyer Leverage Across Partners and Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrecision BioSciences, Inc. faces high customer power because it has no broad commercial base and depends on a few partners, so one collaborator can press on terms, timing, and economics. If its therapies reach market, payers and hospital systems will also have strong leverage; gene therapies like CASGEVY at $2.2M and LYFGENIA at $3.0M show how hard price and reimbursement talks can be. Trial sites and clinicians matter too, since they drive enrollment and adoption.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBuyer\u003c\/th\u003e\n\u003cth\u003ePower\u003c\/th\u003e\n\u003cth\u003eKey fact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartners\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eFew big customers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003e$2.2M-$3.0M CAR-T pricing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinicians\u003c\/td\u003e\n\u003ctd\u003eMed-high\u003c\/td\u003e\n\u003ctd\u003ePhase 1 approval 3%-7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003ePrecision BioSciences, Inc. Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Precision BioSciences, Inc. Porter's Five Forces Analysis you’ll receive after purchase—no samples, no placeholders. It’s the same professionally written, ready-to-use document, formatted for immediate download. What you see here is the final file, so you can buy with confidence knowing there are no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eRivalry Among Competitors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCrowded gene-editing landscape\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCompetitive rivalry is intense because Precision BioSciences, Inc. fights across CRISPR, base-editing, and next-gen nuclease platforms, where many rivals are chasing the same human proof points. The field is capital heavy: Vertex paid $90 million upfront for CRISPR Therapeutics’ sickle cell deal, showing how expensive clinical validation is. \u003c\/p\u003e\n\u003cp\u003eIn gene editing, safety, efficiency, and durability drive differentiation, so even one clean human dataset can reset the ranking. That makes platform performance, not just science, the main edge. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAllogeneic CAR T competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAllogeneic CAR T is a crowded race: Precision BioSciences, Inc. competes with biotech names like Allogene Therapeutics, Caribou Biosciences, and Cellectis, plus large pharma chasing off-the-shelf cell therapy. As of 2025, no off-the-shelf allogeneic CAR T has been FDA-approved in the U.S., so rivals are still fighting for the same cancer targets and first-in-class status. The main battleground is persistence, immune evasion, and lower-cost manufacturing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical milestone pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a Phase 1\/2 clinical-stage company, Precision BioSciences, Inc. is judged on each data cut, safety signal, and proof-of-concept update. In biotech, one stronger readout can reset investor and partner views fast, so rivalry stays intense even before sales begin. A single negative trial can also lift the bar for the whole gene-editing field and pressure peers to show cleaner efficacy and safety.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartnered rivals and incumbents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLarge pharma partners raise rivalry for Precision BioSciences because they pair science with deeper cash, regulator know-how, and bigger sales reach. That means Precision has to win on speed, deal quality, and proof that its gene-editing platform can move fast through clinic and scale into partners’ pipelines. For a smaller company, that makes execution just as important as the science.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBig pharma adds stronger funding\u003c\/li\u003e\n\u003cli\u003eRegulatory history speeds deals\u003c\/li\u003e\n\u003cli\u003eCommercial reach widens rivalry\u003c\/li\u003e\n\u003cli\u003ePrecision must win on speed\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePipeline breadth matters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePrecision BioSciences, Inc. has several ARCUS programs in in vivo editing and allogeneic CAR T, so it can spread risk across more shots on goal. Still, rivals like CRISPR Therapeutics, Intellia Therapeutics, and Caribou Biosciences have deeper cash, broader pipelines, and more advanced clinical data, so rivalry stays high until ARCUS shows clear patient or safety gains.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMultiple programs help, but not enough.\u003c\/li\u003e\n\u003cli\u003eRivals have bigger capital and late-stage assets.\u003c\/li\u003e\n\u003cli\u003eARCUS must prove a real clinical edge.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAllogeneic CAR T Rivalry Heats Up as Proof Gets Pricier\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompetitive rivalry is high: Precision BioSciences, Inc. faces CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences, and Allogene in gene editing and allogeneic CAR T. A $90 million upfront deal for CRISPR Therapeutics shows how costly proof points are.\u003c\/p\u003e\n\u003cp\u003eAs of 2025, no U.S. allogeneic CAR T is FDA-approved, so rivals still compete on safety, persistence, and cleaner human data.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront deal\u003c\/td\u003e\n\u003ctd\u003e$90 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. approved allo CAR T\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSubstitutes Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlternative oncology treatments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThreat of substitutes is high for Precision BioSciences, Inc. because relapsed or refractory cancer patients can still use chemotherapy, targeted therapy, bispecific antibodies, radiation, or supportive care. In the U.S., the American Cancer Society projected 2.0 million new cancer cases in 2025, and many of those patients will choose lower-risk, easier-to-access options over allogeneic CAR T if the benefit gap is small. That caps pricing power and can slow share gains.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutologous CAR T as a substitute\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAutologous CAR T remains a strong substitute because it is clinically established and can deliver high response rates in selected cancers; for example, CD19 CAR T products have shown complete response rates near 40% to 60% in B-cell malignancies. The tradeoff is slow, patient-specific manufacturing, often 2 to 4 weeks, plus complex logistics and cost. Precision BioSciences, Inc. must show its off-the-shelf approach can match these outcomes with faster access and lower friction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOther gene-editing modalities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThreat of substitutes is high for Precision BioSciences, Inc. in in vivo editing because rivals can use RNA drugs, gene replacement, or other editing platforms. As of 2026, more than 20 gene therapies have been approved in the U.S., and many rare diseases still have multiple technical paths. If a rival offers better safety, simpler delivery, or durable benefit, doctors may switch fast, so Precision must prove clear efficacy and lasting edit rates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTransplant and standard-of-care options\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn hematologic cancers, allogeneic stem cell transplant and standard regimens still act as strong substitutes for advanced cell therapies. They are familiar, broadly available, and often reimbursed, so they can meet a 1st-line or relapse need without a new switch. Precision BioSciences, Inc. must prove better response durability and safety versus these entrenched options.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTransplant remains a benchmark option.\u003c\/li\u003e\n\u003cli\u003eStandard regimens are widely covered.\u003c\/li\u003e\n\u003cli\u003eSubstitutes slow adoption of new cell therapy.\u003c\/li\u003e\n\u003cli\u003eClinical benefit must be clear and large.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTrial-stage uncertainty invites substitution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePrecision BioSciences, Inc. is still in development, so weak trial data can quickly push partners and investors toward rival gene-editing platforms. The threat is not just losing one program; it is losing clinical attention and capital to stronger readouts elsewhere. In 2024, this kind of early-stage switching pressure remained high across biotech, where only late-stage or clearly differentiated data keep money in place.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTrial misses can trigger fast reallocation.\u003c\/li\u003e\n\u003cli\u003eSubstitute risk includes capital, not just products.\u003c\/li\u003e\n\u003cli\u003eStronger readouts win partner attention.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision BioSciences Faces Intense Substitute Pressure in Cancer Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of substitutes is high for Precision BioSciences, Inc. because relapsed cancer patients can still choose chemo, targeted drugs, bispecifics, transplant, or supportive care. In 2025, the American Cancer Society projected 2.0 million new U.S. cancer cases, so cheaper and familiar options keep demand pressure high. Autologous CAR T also competes by delivering proven responses, even if manufacturing takes 2 to 4 weeks.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSubstitute\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eChemo and targeted therapy\u003c\/td\u003e\n\u003ctd\u003eLow friction, broad access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAutologous CAR T\u003c\/td\u003e\n\u003ctd\u003eEstablished efficacy, slow turnaround\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTransplant\u003c\/td\u003e\n\u003ctd\u003eStandard benchmark in blood cancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEntrants Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh scientific barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGene editing and allogeneic cell therapy need deep biology, delivery, and immunology expertise, plus long test cycles, so new entrants face a steep wall. Programs often take 5-10 years and tens of millions of dollars before pivotal data, which filters out most startups. That makes Precision BioSciences, Inc.'s field hard to copy fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and clinical hurdles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNew entrants face heavy regulatory and clinical barriers: gene and cell therapies can need years of preclinical work, multi-phase trials, and FDA review, with some programs requiring up to 15 years of post-treatment follow-up. Safety risks like off-target edits, immune reactions, and batch-to-batch manufacturing drift make proof of efficacy and reproducibility much harder. That cost and delay structure keeps fast, low-capital entry out of Precision BioSciences, Inc.'s market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and scale-up difficulty\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCell and gene therapies need GMP manufacturing, tight quality control, and cold-chain logistics, so building a commercial setup from zero can take 18-24 months and heavy capital. New entrants often fail to match batch consistency, which is critical when even small process drift can hurt yield and release rates. Precision BioSciences, Inc.’s existing development infrastructure raises the bar and helps block fast followers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIP and platform protection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePrecision BioSciences, Inc. has a real IP moat: ARCUS and the company’s process know-how make copying harder than in a plain gene-editing shop. That slows new entrants because they may need licenses, workaround designs, or different editing systems before they can compete. The result is a higher entry bar, even though the wider genome-editing field stays active.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eARCUS IP raises imitation costs.\u003c\/li\u003e\n\u003cli\u003eProcess control also matters.\u003c\/li\u003e\n\u003cli\u003eEntrants may need licenses or substitutes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCapital intensity limits entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCapital intensity keeps entry hard in Precision BioSciences, Inc.'s gene-editing space: new biotechs often need tens of millions of dollars before first revenue, while precision medicine R\u0026amp;D spend can run far past $50 million per program. In 2025\/2026, investors still favored firms with validated data, durable IP, and seasoned teams, so newcomers struggled to fund long trials and manufacturing scale-up. That makes the threat of new entrants moderate, not high.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eHigh upfront cash need before sales\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eProof, IP, and team quality matter most\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eLong timelines deter underfunded entrants\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eModerate Entry Threat: IP, Time, and Capital Keep Rivals in Check\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of new entrants is moderate, not high. Precision BioSciences, Inc.'s ARCUS IP, long 5-10 year development cycles, and heavy GMP and FDA hurdles make fast entry costly, while many programs need tens of millions before any revenue. New rivals still appear, but they usually need licenses, data, and strong funding to compete.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBarrier\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e5-10 years\u003c\/td\u003e\n\u003ctd\u003eLonger path to data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTens of millions\u003c\/td\u003e\n\u003ctd\u003eHigh pre-revenue cash need\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eARCUS IP\u003c\/td\u003e\n\u003ctd\u003eRaises imitation cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234298339593,"sku":"dtil-five-forces","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/dtil-five-forces.webp?v=1785717169","url":"https:\/\/dcfanalyst.com\/products\/dtil-five-forces","provider":"DCF Analyst","version":"1.0","type":"link"}